{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:43:04Z","timestamp":1793295784542,"version":"4.5.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T00:00:00Z","timestamp":1748044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T00:00:00Z","timestamp":1748044800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-01206-9","type":"journal-article","created":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T03:47:27Z","timestamp":1748058447000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Pharmacovigilance analysis of neurological adverse events associated with GLP-1 receptor agonists based on the FDA Adverse Event Reporting System"],"prefix":"10.1038","volume":"15","author":[{"given":"He","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sixing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hangyu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiufei","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhishun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,24]]},"reference":[{"key":"1206_CR1","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/s2468-1253(22)00338-7","volume":"8","author":"G Targher","year":"2023","unstructured":"Targher, G., Mantovani, A. & Byrne, C. D. Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease. lancet. Gastroenterol. Hepatol. 8, 179\u2013191. https:\/\/doi.org\/10.1016\/s2468-1253(22)00338-7 (2023).","journal-title":"lancet. Gastroenterol. Hepatol."},{"key":"1206_CR2","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1007\/s00125-023-05906-7","volume":"66","author":"DJ Drucker","year":"2023","unstructured":"Drucker, D. J. & Holst, J. J. The expanding incretin universe: From basic biology to clinical translation. Diabetologia 66, 1765\u20131779. https:\/\/doi.org\/10.1007\/s00125-023-05906-7 (2023).","journal-title":"Diabetologia"},{"key":"1206_CR3","doi-asserted-by":"publisher","first-page":"A4","DOI":"10.1176\/appi.neuropsych.20230226","volume":"36","author":"W L\u00f3pez-Ojeda","year":"2024","unstructured":"L\u00f3pez-Ojeda, W. & Hurley, R. A. Glucagon-Like Peptide 1: An Introduction and Possible Implications for Neuropsychiatry. J. Neuropsychiatry Clin. Neurosci. 36, A4-86. https:\/\/doi.org\/10.1176\/appi.neuropsych.20230226 (2024).","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"1206_CR4","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","volume":"9","author":"Z Zheng","year":"2024","unstructured":"Zheng, Z. et al. Glucagon-like peptide-1 receptor: Mechanisms and advances in therapy. Signal Transduct. Target. Ther. 9, 234. https:\/\/doi.org\/10.1038\/s41392-024-01931-z (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1206_CR5","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1111\/apt.16794","volume":"55","author":"AST Barritt","year":"2022","unstructured":"Barritt, A. S. T., Marshman, E. & Noureddin, M. Review article: Role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes-what hepatologists need to know. Alimentary Pharmacol. Ther. 55, 944\u2013959. https:\/\/doi.org\/10.1111\/apt.16794 (2022).","journal-title":"Alimentary Pharmacol. Ther."},{"key":"1206_CR6","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1038\/s41591-024-03015-5","volume":"30","author":"HM Colhoun","year":"2024","unstructured":"Colhoun, H. M. et al. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nat. Med. 30, 2058\u20132066. https:\/\/doi.org\/10.1038\/s41591-024-03015-5 (2024).","journal-title":"Nat. Med."},{"key":"1206_CR7","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/oby.23621","volume":"31","author":"I Lingvay","year":"2023","unstructured":"Lingvay, I. et al. Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics. Obesity (Silver Spring, Md.) 31, 111\u2013122. https:\/\/doi.org\/10.1002\/oby.23621 (2023).","journal-title":"Obesity (Silver Spring, Md.)"},{"key":"1206_CR8","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","volume":"384","author":"PN Newsome","year":"2021","unstructured":"Newsome, P. N. et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N. Engl. J. Med. 384, 1113\u20131124. https:\/\/doi.org\/10.1056\/NEJMoa2028395 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1206_CR74","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/jamainternmed.2022.0338","volume":"182","author":"L He","year":"2022","unstructured":"He, L. et al. Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: A systematic review and meta-analysis of randomized clinical trials. JAMA Intern. Med. 182, 513\u2013519. https:\/\/doi.org\/10.1001\/jamainternmed.2022.0338 (2022).","journal-title":"JAMA Intern. Med."},{"key":"1206_CR75","doi-asserted-by":"publisher","first-page":"384","DOI":"10.2337\/dc22-1148","volume":"46","author":"J Bezin","year":"2023","unstructured":"Bezin, J. et al. GLP-1 receptor agonists and the risk of thyroid cancer. Diabete. Care 46, 384\u2013390. https:\/\/doi.org\/10.2337\/dc22-1148 (2023).","journal-title":"Diabete. Care"},{"key":"1206_CR76","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03412-w","author":"Y Xie","year":"2025","unstructured":"Xie, Y., Choi, T. & Al-Aly, Z. Mapping the effectiveness and risks of GLP-1 receptor agonists. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-024-03412-w (2025).","journal-title":"Nat. Med."},{"key":"1206_CR9","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12916-024-03274-6","volume":"22","author":"J Zhou","year":"2024","unstructured":"Zhou, J. et al. Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: A pharmacovigilance study based on the FDA adverse event reporting system database. BMC Med. 22, 65. https:\/\/doi.org\/10.1186\/s12916-024-03274-6 (2024).","journal-title":"BMC Med."},{"key":"1206_CR10","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1900\/rds.2014.11.202","volume":"11","author":"TD Filippatos","year":"2014","unstructured":"Filippatos, T. D., Panagiotopoulou, T. V. & Elisaf, M. S. Adverse effects of GLP-1 receptor agonists. Rev. Diabet. Stud.: RDS 11, 202\u2013230. https:\/\/doi.org\/10.1900\/rds.2014.11.202 (2014).","journal-title":"Rev. Diabet. Stud.: RDS"},{"key":"1206_CR11","unstructured":"The Food and drug administration (FDA), FDA adverse event reporting system (FAERS) database, https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-adverse-event-reporting-system-faers-database Accessed 2 December 2024."},{"key":"1206_CR12","unstructured":"R Core Team R: A Language and environment for statistical computing. r foundation for statistical computing, Vienna, Austria. https:\/\/www.R-project.org\/(2024)."},{"key":"1206_CR13","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli, M. et al. The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in pharmacovigilance (READUS-PV): Development and statement. Drug Saf. 47, 575\u2013584. https:\/\/doi.org\/10.1007\/s40264-024-01421-9 (2024).","journal-title":"Drug Saf."},{"key":"1206_CR14","unstructured":"U.S. Food and Drug Administration, FDA Adverse Event Reporting System (FAERS) Database, https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-adverse-event-reporting-system-faers-database, Accessed 2 November 2024."},{"key":"1206_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101967","volume":"59","author":"C Zhou","year":"2023","unstructured":"Zhou, C. et al. Psychiatric disorders associated with immune checkpoint inhibitors: A pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database. EClinicalMedicine 59, 101967. https:\/\/doi.org\/10.1016\/j.eclinm.2023.101967 (2023).","journal-title":"EClinicalMedicine"},{"key":"1206_CR16","doi-asserted-by":"publisher","first-page":"1330936","DOI":"10.3389\/fendo.2024.1330936","volume":"15","author":"W Chen","year":"2024","unstructured":"Chen, W., Cai, P., Zou, W. & Fu, Z. Psychiatric adverse events associated with GLP-1 receptor agonists: A real-world pharmacovigilance study based on the FDA adverse event reporting system database. Front. Endocrinol. 15, 1330936. https:\/\/doi.org\/10.3389\/fendo.2024.1330936 (2024).","journal-title":"Front. Endocrinol."},{"key":"1206_CR17","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/s40425-019-0754-2","volume":"7","author":"Y Zhai","year":"2019","unstructured":"Zhai, Y. et al. Endocrine toxicity of immune checkpoint inhibitors: A real-world study leveraging US food and drug administration adverse events reporting system. J. Immunother. Cancer 7, 286. https:\/\/doi.org\/10.1186\/s40425-019-0754-2 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"1206_CR18","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/jcpt.13024","volume":"45","author":"S Kinoshita","year":"2020","unstructured":"Kinoshita, S., Hosomi, K., Yokoyama, S. & Takada, M. Time-to-onset analysis of amiodarone-associated thyroid dysfunction. J. Clin. Pharm. Ther. 45, 65\u201371. https:\/\/doi.org\/10.1111\/jcpt.13024 (2020).","journal-title":"J. Clin. Pharm. Ther."},{"key":"1206_CR19","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s40264-013-0061-7","volume":"36","author":"O Sauzet","year":"2013","unstructured":"Sauzet, O., Carvajal, A., Escudero, A., Molokhia, M. & Cornelius, V. R. Illustration of the weibull shape parameter signal detection tool using electronic healthcare record data. Drug Saf. 36, 995\u20131006. https:\/\/doi.org\/10.1007\/s40264-013-0061-7 (2013).","journal-title":"Drug Saf."},{"key":"1206_CR20","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s40264-020-00911-w","volume":"43","author":"O Caster","year":"2020","unstructured":"Caster, O., Aoki, Y., Gattepaille, L. M. & Grundmark, B. Disproportionality analysis for pharmacovigilance signal detection in small databases or subsets: Recommendations for limiting false-positive associations. Drug Saf. 43, 479\u2013487. https:\/\/doi.org\/10.1007\/s40264-020-00911-w (2020).","journal-title":"Drug Saf."},{"key":"1206_CR21","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman, K. J., Lanes, S. & Sacks, S. T. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol. Drug Saf. 13, 519\u2013523. https:\/\/doi.org\/10.1002\/pds.1001 (2004).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"1206_CR22","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans, S. J., Waller, P. C. & Davis, S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol. Drug Saf. 10, 483\u2013486. https:\/\/doi.org\/10.1002\/pds.677 (2001).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"1206_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0028124","volume":"6","author":"T Sakaeda","year":"2011","unstructured":"Sakaeda, T., Kadoyama, K. & Okuno, Y. Statin-associated muscular and renal adverse events: Data mining of the public version of the FDA adverse event reporting system. PLoS ONE 6, e28124. https:\/\/doi.org\/10.1371\/journal.pone.0028124 (2011).","journal-title":"PLoS ONE"},{"key":"1206_CR24","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate, A. & Evans, S. J. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol. Drug Saf. 18, 427\u2013436. https:\/\/doi.org\/10.1002\/pds.1742 (2009).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"1206_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101535","volume":"50","author":"YD Yan","year":"2022","unstructured":"Yan, Y. D. et al. Toxicity spectrum of immunotherapy in advanced lung cancer: A safety analysis from clinical trials and a pharmacovigilance system. EClinicalMedicine 50, 101535. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101535 (2022).","journal-title":"EClinicalMedicine"},{"key":"1206_CR26","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","volume":"53","author":"W DuMouchel","year":"1999","unstructured":"DuMouchel, W. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. Am. Stat. 53, 177\u2013190 (1999).","journal-title":"Am. Stat."},{"key":"1206_CR27","doi-asserted-by":"crossref","unstructured":"Szarfman, A., Tonning, J. M. & Doraiswamy, P. M. Vol. 24 1099\u20131104 (Wiley Online Library, 2004).","DOI":"10.1592\/phco.24.13.1099.38090"},{"key":"1206_CR28","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s10194-024-01913-0","volume":"25","author":"WH Liu","year":"2024","unstructured":"Liu, W. H. et al. Real-world study of adverse events associated with triptan use in migraine treatment based on the U.S. food and drug administration (FDA) adverse event reporting system (FAERS) database. J. Headache pain 25, 206. https:\/\/doi.org\/10.1186\/s10194-024-01913-0 (2024).","journal-title":"J. Headache pain"},{"key":"1206_CR29","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/s0140-6736(24)02317-1","volume":"404","author":"Worldwide trends in diabetes prevalence and treatment from 1990 \u2013 2022","year":"2024","unstructured":"Worldwide trends in diabetes prevalence and treatment from 1990 \u2013 2022. A pooled analysis of 1108 population-representative studies with 141 million participants. Lancet (London, England) 404, 2077\u20132093. https:\/\/doi.org\/10.1016\/s0140-6736(24)02317-1 (2024).","journal-title":"Lancet (London, England)"},{"key":"1206_CR30","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12933-023-01765-z","volume":"22","author":"RM Sandsdal","year":"2023","unstructured":"Sandsdal, R. M. et al. Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: A randomized controlled trial. Cardiovasc. Diabetol. 22, 41. https:\/\/doi.org\/10.1186\/s12933-023-01765-z (2023).","journal-title":"Cardiovasc. Diabetol."},{"key":"1206_CR31","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.7150\/ijbs.59965","volume":"17","author":"X Ma","year":"2021","unstructured":"Ma, X. et al. GLP-1 receptor agonists (GLP-1RAs): Cardiovascular actions and therapeutic potential. Int. J. Biol. Sci. 17, 2050\u20132068. https:\/\/doi.org\/10.7150\/ijbs.59965 (2021).","journal-title":"Int. J. Biol. Sci."},{"key":"1206_CR32","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1161\/circulationaha.123.067584","volume":"149","author":"BL Neuen","year":"2024","unstructured":"Neuen, B. L. et al. Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal mra compared with conventional care in patients with type 2 diabetes and albuminuria. Circulation 149, 450\u2013462. https:\/\/doi.org\/10.1161\/circulationaha.123.067584 (2024).","journal-title":"Circulation"},{"key":"1206_CR33","doi-asserted-by":"publisher","first-page":"1043789","DOI":"10.3389\/fendo.2022.1043789","volume":"13","author":"L Liu","year":"2022","unstructured":"Liu, L., Chen, J., Wang, L., Chen, C. & Chen, L. Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database. Front. Endocrinol. 13, 1043789. https:\/\/doi.org\/10.3389\/fendo.2022.1043789 (2022).","journal-title":"Front. Endocrinol."},{"key":"1206_CR34","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-024-04112-8","author":"J Zhou","year":"2024","unstructured":"Zhou, J. et al. Risk of ophthalmic adverse drug reactions in patients prescribed glucagon-like peptide 1 receptor agonists: A pharmacovigilance study based on the FDA adverse event reporting system database. Endocrine https:\/\/doi.org\/10.1007\/s12020-024-04112-8 (2024).","journal-title":"Endocrine"},{"key":"1206_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3070","volume":"35","author":"R Gentilella","year":"2019","unstructured":"Gentilella, R., Pechtner, V., Corcos, A. & Consoli, A. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: Are they all the same?. Diabete. Metab. Res. Rev. 35, e3070. https:\/\/doi.org\/10.1002\/dmrr.3070 (2019).","journal-title":"Diabete. Metab. Res. Rev."},{"key":"1206_CR36","unstructured":"Institute for Health Metrics and Evaluation, GBD Results, https:\/\/vizhub.healthdata.org\/gbd-results\/, Accessed 24 November 2024."},{"key":"1206_CR37","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.14336\/ad.2019.0303","volume":"10","author":"L Gao","year":"2019","unstructured":"Gao, L. et al. Neurological manifestation of incretin-based therapies in patients with type 2 diabetes: A systematic review and network meta-analysis. Aging Dis. 10, 1311\u20131319. https:\/\/doi.org\/10.14336\/ad.2019.0303 (2019).","journal-title":"Aging Dis."},{"key":"1206_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12982-015-0037-4","volume":"12","author":"KM Fedak","year":"2015","unstructured":"Fedak, K. M., Bernal, A., Capshaw, Z. A. & Gross, S. Applying the Bradford Hill criteria in the 21st century: How data integration has changed causal inference in molecular epidemiology. Emerg. Theme. Epidemiol. 12, 1\u20139 (2015).","journal-title":"Emerg. Theme. Epidemiol."},{"key":"1206_CR39","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.21037\/atm-21-4162","volume":"9","author":"Z Zhao","year":"2021","unstructured":"Zhao, Z. et al. Hypoglycemia following the use of glucagon-like peptide-1 receptor agonists: A real-world analysis of post-marketing surveillance data. Ann. Transl. Med. 9, 1482. https:\/\/doi.org\/10.21037\/atm-21-4162 (2021).","journal-title":"Ann. Transl. Med."},{"key":"1206_CR40","doi-asserted-by":"crossref","unstructured":"Aljihmani, L. et al. In 2019 IEEE International Smart Cities Conference (ISC2). 268\u2013271 (IEEE).","DOI":"10.1109\/ISC246665.2019.9071646"},{"key":"1206_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.physbeh.2024.114793","volume":"291","author":"R Khan","year":"2025","unstructured":"Khan, R. & Doty, R. L. GLP-1 receptor agonists significantly impair taste function. Physiol. Behav. 291, 114793. https:\/\/doi.org\/10.1016\/j.physbeh.2024.114793 (2025).","journal-title":"Physiol. Behav."},{"key":"1206_CR42","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.2169\/internalmedicine.2608-23","volume":"63","author":"S Okada","year":"2024","unstructured":"Okada, S. et al. Hot water eliminates the bitter taste of oral semaglutide: A report of four cases. Int. Med. (Tokyo, Japan) 63, 2297\u20132300. https:\/\/doi.org\/10.2169\/internalmedicine.2608-23 (2024).","journal-title":"Int. Med. (Tokyo, Japan)"},{"key":"1206_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11164641","author":"D Merino","year":"2022","unstructured":"Merino, D. et al. Drug-associated parosmia: New perspectives from the WHO safety database. J. clin. Med. https:\/\/doi.org\/10.3390\/jcm11164641 (2022).","journal-title":"J. clin. Med."},{"key":"1206_CR44","first-page":"41","volume":"2","author":"H-M Back","year":"2023","unstructured":"Back, H.-M., Choi, S.-A. & Kim, M. G. Adverse events of GLP-1 receptor agonists for weight loss: Twitter and a national pharmacovigilance database. Drug Targ. Ther. 2, 41\u201348 (2023).","journal-title":"Drug Targ. Ther."},{"key":"1206_CR45","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/j.1749-6632.2009.03920.x","volume":"1170","author":"B Martin","year":"2009","unstructured":"Martin, B. et al. Modulation of taste sensitivity by GLP-1 signaling in taste buds. Ann. N. Y. Acad. Sci. 1170, 98\u2013101. https:\/\/doi.org\/10.1111\/j.1749-6632.2009.03920.x (2009).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"1206_CR46","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1016\/j.dsx.2019.06.021","volume":"13","author":"MC Brindisi","year":"2019","unstructured":"Brindisi, M. C. et al. Proof of concept: Effect of GLP-1 agonist on food hedonic responses and taste sensitivity in poor controlled type 2 diabetic patients. Diabet. Metab. Syndr. 13, 2489\u20132494. https:\/\/doi.org\/10.1016\/j.dsx.2019.06.021 (2019).","journal-title":"Diabet. Metab. Syndr."},{"issue":"bvae163","key":"1206_CR47","first-page":"013","volume":"8","author":"MJ Sever","year":"2024","unstructured":"Sever, M. J. et al. 6468 Once-Weekly Semaglutide and Taste Perception in Women with Obesity. J. Endocr. Soc. 8(bvae163), 013 (2024).","journal-title":"J. Endocr. Soc."},{"key":"1206_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2023.101738","volume":"73","author":"M Montaner","year":"2023","unstructured":"Montaner, M. et al. The local GLP-1 system in the olfactory bulb is required for odor-evoked cephalic phase of insulin release in mice. Mol. Metab. 73, 101738. https:\/\/doi.org\/10.1016\/j.molmet.2023.101738 (2023).","journal-title":"Mol. Metab."},{"key":"1206_CR49","doi-asserted-by":"publisher","first-page":"6941","DOI":"10.1038\/s41467-024-51076-4","volume":"15","author":"M Montaner","year":"2024","unstructured":"Montaner, M. et al. A neuronal circuit driven by GLP-1 in the olfactory bulb regulates insulin secretion. Nat. Commun. 15, 6941. https:\/\/doi.org\/10.1038\/s41467-024-51076-4 (2024).","journal-title":"Nat. Commun."},{"key":"1206_CR50","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/s42255-021-00344-4","volume":"3","author":"DI Brierley","year":"2021","unstructured":"Brierley, D. I. et al. Central and peripheral GLP-1 systems independently suppress eating. Nat. Metab. 3, 258\u2013273. https:\/\/doi.org\/10.1038\/s42255-021-00344-4 (2021).","journal-title":"Nat. Metab."},{"key":"1206_CR51","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2337\/db18-0729","volume":"68","author":"MK Holt","year":"2019","unstructured":"Holt, M. K. et al. Preproglucagon neurons in the nucleus of the solitary tract are the main source of brain GLP-1, mediate stress-induced hypophagia, and limit unusually large intakes of food. Diabetes 68, 21\u201333. https:\/\/doi.org\/10.2337\/db18-0729 (2019).","journal-title":"Diabetes"},{"key":"1206_CR52","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.neuroscience.2011.02.023","volume":"180","author":"IJ Llewellyn-Smith","year":"2011","unstructured":"Llewellyn-Smith, I. J., Reimann, F., Gribble, F. M. & Trapp, S. Preproglucagon neurons project widely to autonomic control areas in the mouse brain. Neuroscience 180, 111\u2013121. https:\/\/doi.org\/10.1016\/j.neuroscience.2011.02.023 (2011).","journal-title":"Neuroscience"},{"key":"1206_CR53","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1210\/endrev\/bnaa032","volume":"42","author":"BA McLean","year":"2021","unstructured":"McLean, B. A. et al. Revisiting the complexity of GLP-1 action from sites of synthesis to receptor activation. Endocr. Rev. 42, 101\u2013132. https:\/\/doi.org\/10.1210\/endrev\/bnaa032 (2021).","journal-title":"Endocr. Rev."},{"key":"1206_CR54","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.autneu.2003.11.001","volume":"110","author":"A Nakagawa","year":"2004","unstructured":"Nakagawa, A. et al. Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells. Auton. Neurosci.: Basic. Clin. 110, 36\u201343. https:\/\/doi.org\/10.1016\/j.autneu.2003.11.001 (2004).","journal-title":"Auton. Neurosci.: Basic. Clin."},{"key":"1206_CR55","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.physbeh.2014.06.015","volume":"135","author":"CC Ronveaux","year":"2014","unstructured":"Ronveaux, C. C., de Lartigue, G. & Raybould, H. E. Ability of GLP-1 to decrease food intake is dependent on nutritional status. Physiol. Behav. 135, 222\u2013229. https:\/\/doi.org\/10.1016\/j.physbeh.2014.06.015 (2014).","journal-title":"Physiol. Behav."},{"key":"1206_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s1566-0702(00)00215-0","volume":"85","author":"HR Berthoud","year":"2000","unstructured":"Berthoud, H. R. & Neuhuber, W. L. Functional and chemical anatomy of the afferent vagal system. Auton. Neurosci.\u202f: Basic clin. 85, 1\u201317. https:\/\/doi.org\/10.1016\/s1566-0702(00)00215-0 (2000).","journal-title":"Auton. Neurosci. : Basic clin."},{"key":"1206_CR57","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.mayocp.2019.02.018","volume":"94","author":"S Sinha","year":"2019","unstructured":"Sinha, S., Kataria, A., Kolla, B. P., Thusius, N. & Loukianova, L. L. Wernicke encephalopathy-clinical pearls. Mayo Clin. Proc. 94, 1065\u20131072. https:\/\/doi.org\/10.1016\/j.mayocp.2019.02.018 (2019).","journal-title":"Mayo Clin. Proc."},{"key":"1206_CR58","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/s1474-4422(07)70104-7","volume":"6","author":"G Sechi","year":"2007","unstructured":"Sechi, G. & Serra, A. Wernicke\u2019s encephalopathy: New clinical settings and recent advances in diagnosis and management. Lancet. Neurol. 6, 442\u2013455. https:\/\/doi.org\/10.1016\/s1474-4422(07)70104-7 (2007).","journal-title":"Lancet. Neurol."},{"key":"1206_CR59","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.61783","volume":"16","author":"K Sheth","year":"2024","unstructured":"Sheth, K., Garza, E., Saju, A., Nazir, N. & Agarwal, A. Wernicke encephalopathy associated with semaglutide Use. Cureus 16, e61783. https:\/\/doi.org\/10.7759\/cureus.61783 (2024).","journal-title":"Cureus"},{"key":"1206_CR60","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci13111503","author":"D Arillotta","year":"2023","unstructured":"Arillotta, D. et al. GLP-1 receptor agonists and related mental health issues; insights from a range of social media platforms using a mixed-methods approach. Brain sci. https:\/\/doi.org\/10.3390\/brainsci13111503 (2023).","journal-title":"Brain sci."},{"key":"1206_CR61","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s10194-024-01821-3","volume":"25","author":"W Halloum","year":"2024","unstructured":"Halloum, W., Dughem, Y. A., Beier, D. & Pellesi, L. Glucagon-like peptide-1 (GLP-1) receptor agonists for headache and pain disorders: A systematic review. J. Headache Pain 25, 112. https:\/\/doi.org\/10.1186\/s10194-024-01821-3 (2024).","journal-title":"J. Headache Pain"},{"key":"1206_CR62","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1038\/s12276-024-01342-8","volume":"56","author":"EJ Go","year":"2024","unstructured":"Go, E. J. et al. GLP-1 and its derived peptides mediate pain relief through direct TRPV1 inhibition without affecting thermoregulation. Exp. Mol. Med. 56, 2449\u20132464. https:\/\/doi.org\/10.1038\/s12276-024-01342-8 (2024).","journal-title":"Exp. Mol. Med."},{"key":"1206_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2023.137397","volume":"812","author":"F Jing","year":"2023","unstructured":"Jing, F., Zou, Q. & Pu, Y. GLP-1R agonist liraglutide attenuates pain hypersensitivity by stimulating IL-10 release in a nitroglycerin-induced chronic migraine mouse model. Neurosci. Lett. 812, 137397. https:\/\/doi.org\/10.1016\/j.neulet.2023.137397 (2023).","journal-title":"Neurosci. Lett."},{"key":"1206_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2022.109806","volume":"186","author":"Q Zhang","year":"2022","unstructured":"Zhang, Q. et al. Glucagon-like peptide-1 receptor agonist attenuates diabetic neuropathic pain via inhibition of NOD-like receptor protein 3 inflammasome in brain microglia. Diabetes Res. Clin. Pract. 186, 109806. https:\/\/doi.org\/10.1016\/j.diabres.2022.109806 (2022).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"1206_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118645","volume":"264","author":"H Yaribeygi","year":"2021","unstructured":"Yaribeygi, H., Rashidy-Pour, A., Atkin, S. L., Jamialahmadi, T. & Sahebkar, A. GLP-1 mimetics and cognition. Life Sci. 264, 118645. https:\/\/doi.org\/10.1016\/j.lfs.2020.118645 (2021).","journal-title":"Life Sci."},{"key":"1206_CR66","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.tem.2016.10.001","volume":"28","author":"G Muscogiuri","year":"2017","unstructured":"Muscogiuri, G., DeFronzo, R. A., Gastaldelli, A. & Holst, J. J. Glucagon-like peptide-1 and the central\/peripheral nervous system: Crosstalk in diabetes. Trend. Endocrinol. Metab. 28, 88\u2013103. https:\/\/doi.org\/10.1016\/j.tem.2016.10.001 (2017).","journal-title":"Trend. Endocrinol. Metab."},{"key":"1206_CR67","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/(sici)1096-9861(19990111)403:2<261::aid-cne8>3.0.co;2-5","volume":"403","author":"I Merchenthaler","year":"1999","unstructured":"Merchenthaler, I., Lane, M. & Shughrue, P. Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J. Comp. Neurol. 403, 261\u2013280. https:\/\/doi.org\/10.1002\/(sici)1096-9861(19990111)403:2%3c261::aid-cne8%3e3.0.co;2-5 (1999).","journal-title":"J. Comp. Neurol."},{"key":"1206_CR68","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1210\/en.2013-1934","volume":"155","author":"C Pyke","year":"2014","unstructured":"Pyke, C. et al. GLP-1 receptor localization in monkey and human tissue: Novel distribution revealed with extensively validated monoclonal antibody. Endocrinology 155, 1280\u20131290. https:\/\/doi.org\/10.1210\/en.2013-1934 (2014).","journal-title":"Endocrinology"},{"key":"1206_CR69","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.drudis.2016.01.013","volume":"21","author":"D Athauda","year":"2016","unstructured":"Athauda, D. & Foltynie, T. The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson\u2019s disease: Mechanisms of action. Drug Discov. Today 21, 802\u2013818. https:\/\/doi.org\/10.1016\/j.drudis.2016.01.013 (2016).","journal-title":"Drug Discov. Today"},{"key":"1206_CR70","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","volume":"30","author":"TD M\u00fcller","year":"2019","unstructured":"M\u00fcller, T. D. et al. Glucagon-like peptide 1 (GLP-1). Mol. Metab. 30, 72\u2013130. https:\/\/doi.org\/10.1016\/j.molmet.2019.09.010 (2019).","journal-title":"Mol. Metab."},{"key":"1206_CR71","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1111\/dom.12251","volume":"16","author":"J Seufert","year":"2014","unstructured":"Seufert, J. & Gallwitz, B. The extra-pancreatic effects of GLP-1 receptor agonists: A focus on the cardiovascular, gastrointestinal and central nervous systems. Diabet. Obes. Metab. 16, 673\u2013688. https:\/\/doi.org\/10.1111\/dom.12251 (2014).","journal-title":"Diabet. Obes. Metab."},{"key":"1206_CR72","doi-asserted-by":"publisher","first-page":"11367","DOI":"10.1038\/s41598-024-62238-1","volume":"14","author":"G Yin","year":"2024","unstructured":"Yin, G., Song, G., Xue, S. & Liu, F. Adverse event signal mining and serious adverse event influencing factor analysis of fulvestrant based on FAERS database. Sci. Rep. 14, 11367. https:\/\/doi.org\/10.1038\/s41598-024-62238-1 (2024).","journal-title":"Sci. Rep."},{"key":"1206_CR73","doi-asserted-by":"publisher","DOI":"10.3389\/fdsfr.2023.1323057","author":"PM Cutroneo","year":"2024","unstructured":"Cutroneo, P. M. et al. Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems. Front. Drug Saf. Regul. https:\/\/doi.org\/10.3389\/fdsfr.2023.1323057 (2024).","journal-title":"Front. Drug Saf. Regul."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-01206-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-01206-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-01206-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T03:47:30Z","timestamp":1748058450000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-01206-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,24]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1206"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-01206-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,24]]},"assertion":[{"value":"17 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18063"}}